Alderuccio F, Barnett A J, Campbell J H, Pedersen J S, Toh B H
Clin Exp Immunol. 1986 Apr;64(1):94-100.
Thirteen out of 60 sera (22%) from patients with progressive systemic sclerosis reacted by immunoblotting with a doublet of 95 kD and 100 kD proteins in endothelial cells of human and bovine origin. Reactivity with the doublet was not seen in any of 125 control sera. The endothelial doublet was localized to the nucleus by immunoblot reactivity with nuclear subcellular fractions but not with mitochondrial, microsomal or soluble subcellular fractions. In HEp-2 cells and in HeLa cells, positive sera reacted with the 100 kD antigen, but not with the 95 kD antigen. Identical immunoblot reactivity was obtained with a standard reference serum containing anti-scl-70 activity by immunodiffusion. All positive sera also reacted with cell nuclei by indirect immunofluorescence and 10 gave anti-scl-70 reactivity by immunodiffusion. These observations suggest that the 95 kD/100 kD doublet may be a larger form of the Scl-70 autoantigen.
在进行性系统性硬化症患者的60份血清中,有13份(22%)通过免疫印迹法与人和牛来源内皮细胞中的95kD和100kD双蛋白条带发生反应。在125份对照血清中均未观察到与该双蛋白条带的反应性。通过与细胞核亚细胞组分的免疫印迹反应性,内皮双蛋白条带定位于细胞核,而与线粒体、微粒体或可溶性亚细胞组分无反应。在HEp-2细胞和HeLa细胞中,阳性血清与100kD抗原发生反应,但不与95kD抗原反应。通过免疫扩散,含有抗scl-70活性的标准参考血清获得了相同的免疫印迹反应性。所有阳性血清通过间接免疫荧光也与细胞核发生反应,其中10份通过免疫扩散呈现抗scl-70反应性。这些观察结果表明,95kD/100kD双蛋白条带可能是Scl-70自身抗原的一种更大形式。